These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8097925)

  • 41. Atenolol in the treatment of angina pectoris.
    Erikssen J; Osvik K; Dedichen J
    Acta Med Scand; 1977; 201(6):579-84. PubMed ID: 17996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.
    Wilcox RG; Hampton JR
    Br J Clin Pharmacol; 1982 Jun; 13(6):841-6. PubMed ID: 6124268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute and long-term hemodynamic effects of tiapamil at rest and during exercise in essential hypertension.
    Omvik P; Lund-Johansen P
    Cardiovasc Drugs Ther; 1989 Aug; 3(4):517-23. PubMed ID: 2488103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pharmacology of epanolol (ICI 141292)--a new beta 1-selective adrenoceptor partial agonist.
    Bilski AJ; Hadfield SE; Wale JL
    J Cardiovasc Pharmacol; 1988 Aug; 12(2):227-32. PubMed ID: 2459554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of carvedilol and atenolol for angina pectoris.
    Freedman SB; Jamal SM; Harris PJ; Kelly DT
    Am J Cardiol; 1987 Sep; 60(7):499-502. PubMed ID: 2888302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
    Rousseau MF; Pouleur H; Cocco G; Wolff AA
    Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atenolol and three nonselective beta-blockers in hypertension.
    Waal-Manning HJ
    Clin Pharmacol Ther; 1979 Jan; 25(1):8-18. PubMed ID: 31259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term systemic hemodynamic adaptation to beta-adrenergic inhibition with atenolol in hypertensive patients.
    Simon G; Franciosa JA; Gimenez HJ; Cohn JN
    Hypertension; 1981; 3(2):262-8. PubMed ID: 6111532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease.
    Silke B; Verma SP; Sharma SK; Frais MA; Reynolds G; Taylor SH
    J Cardiovasc Pharmacol; 1989 Jan; 13(1):155-61. PubMed ID: 2468927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.
    Dixon MS; Thomas P; Sheridan DJ
    Eur J Clin Pharmacol; 1990; 38(1):21-4. PubMed ID: 1970298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension.
    Panfilov V; Morris AD; Donnelly R; Scemama M; Reid JL
    Br J Clin Pharmacol; 1995 Dec; 40(6):563-9. PubMed ID: 8703663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunction.
    Van Den Heuvel AF; van der Ent M; van Veldhuisen DJ; Kruijssen DA; Bartels GL; Remme WJ
    J Cardiovasc Pharmacol; 1998 Apr; 31(4):506-12. PubMed ID: 9554797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
    Schiffrin EL; Park JB; Pu Q
    J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term hemodynamic effects of antihypertensive treatment.
    Lund-Johansen P; Omvik P; Nordrehaug JE
    Clin Investig; 1992; 70 Suppl 1():S58-64. PubMed ID: 1350486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The influence of beta-adrenoceptor antagonists with and without partial agonist activity on exercise tolerance and muscle lactate production.
    Lees KR; Curzio J; Farish E; Borland WW; Rubin PC
    Eur J Clin Pharmacol; 1987; 33(4):415-7. PubMed ID: 2894994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pafenolol in hypertension: a double-blind randomized trial of a new beta 1-selective adrenoceptor blocker.
    Dahlöf B; Sjöberg KH; Flygt C; Jern S; Hansen S; Hansson L
    J Cardiovasc Pharmacol; 1986; 8(1):55-9. PubMed ID: 2419693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An overview of clinical trial experience with epanolol.
    Blake P
    Drugs; 1989; 38 Suppl 2():81-5. PubMed ID: 2575988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
    Lund-Johansen P
    Drugs; 1984; 28 Suppl 2():35-50. PubMed ID: 6151890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow-up study of atenolol.
    Lund-Johansen P
    J Cardiovasc Pharmacol; 1979; 1(5):487-95. PubMed ID: 94405
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new water-soluble, selective beta-blocker with intrinsic sympathomimetic activity (ICI 141.292) in angina pectoris.
    Erikssen J; Rollag A; Otterstad JE
    Acta Med Scand; 1988; 223(1):35-43. PubMed ID: 2894747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.